5Zhong N,Wang C,Yao W,et al.Prevalence of chronic obstructive pulmonary diseasein China:a large,populationbased survey[J].Am J Respir Cfit Care Med,2007(176):753-760.
6Levy MM,Fink MP,Marshall JC,et al.2001 SCCM/ESKM/ACCP/ATS/SIS international Sepsis Definitions Conference[J].Crit Care Med,2003(1):250-256.
7Falk JA, Minai OA, Mosenifar Z. Inhaled and systemic corticoste- roids in chronic obstructive pulmonary disease [ J]. Proc Am Tho- rac Soc,2008,5 (4) :506 - 512.
8Singh S, Loke YK. An overview of the benefits and drawbacks of inhaled corticostemids in chronic obstructive pulmonary disease [ J]. Int J Chron Obstruct Pulmon Dis,2010,5 ( 15 ) : 189 - 195.
9Leuppi JD, Schuetz P, Bingisser R, et al. Short-term vs convention- al glucocorticoid therapy in acute exacerbations of chronic obstruc- tive pulmonary disease the REDUCE randomized clinical trial[ J]. JAMA,2013,309 ( 21 ) : 2223 - 2231.
10Lindenauer PK, Pekow PS, Lahti MC, et al. Association of cortico- steroid dose and route of administration with risk of treatment fail- ure in acute exacerbation of chronic obstructive pulmonary disease [ J ]. JAMA,2010,303 ( 23 ) :2359 - 2367.
